3-烯丙基-2-(烯丙氧基)苯甲醛 | 84682-15-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3-烯丙基-2-(烯丙氧基)苯甲醛
• 中文别名: 3-(烯丙基氨基)-2-(烯丙氧基)苯甲醛
• 英文名称: 3-allyl-2-(allyloxy)benzaldehyde
• 英文别名: 2-prop-2-enoxy-3-prop-2-enylbenzaldehyde
• CAS: 84682-15-5
• 化学式: C₁₃H₁₄O₂
• 分子量: 202.253
• InChiKey: YIZHWEKWDRJEKT-UHFFFAOYSA-N

物化性质

• 沸点：
  313.6±30.0 °C(Predicted)
• 密度：
  1.023±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2912499000

反应信息

• 作为反应物：
  描述：

  3-烯丙基-2-(烯丙氧基)苯甲醛 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 [RuHCl(CO)(PPh₃)₃] 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 20.0h， 生成 苯并[b]呋喃-7-甲醛
  参考文献：
  名称：

  An isomerization-ring-closing metathesis strategy for the synthesis of substituted benzofurans

  摘要：

  Twelve substituted benzofurans were synthesized from their corresponding substituted l-allyl-2-allyloxybenzenes using ruthenium-mediated G and O-allyl isomerization followed by ring-closing metathesis. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2005.05.090
• 作为产物：
  描述：

  邻丙烯基氧基苯甲醛 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 2.0h， 生成 3-烯丙基-2-(烯丙氧基)苯甲醛
  参考文献：
  名称：

  An isomerization-ring-closing metathesis strategy for the synthesis of substituted benzofurans

  摘要：

  Twelve substituted benzofurans were synthesized from their corresponding substituted l-allyl-2-allyloxybenzenes using ruthenium-mediated G and O-allyl isomerization followed by ring-closing metathesis. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2005.05.090

文献信息

• A cascade Claisen rearrangement/o-quinone methide formation/electrocyclization approach to 2H-chromenes
  作者：Liyan Song、Fang Huang、Liwen Guo、Ming-An Ouyang、Rongbiao Tong

  DOI：10.1039/c7cc03037a

  日期：——

  new approach has been developed for the synthesis of 8-substituted 2H-chromenes, featuring a novel cascade aromatic Claisen rearrangement/o-quinone methide formation/6π-electrocyclization. This new method was demonstrated with 28 examples tolerating different substitutions at alkenes, allylic and aromatic ring and with total syntheses of three 2H-chromene natural products.

  已经开发出用于合成8-取代的2 H-色烯的新方法，其特征在于新颖的级联芳族克莱森重排/邻醌甲基化物形成/6π-电环化。28个实例可以耐受烯烃，烯丙基和芳环的不同取代，并可以合成三种2 H-色烯天然产物，从而证明了这种新方法。
• Synthesis of Chromenoisoxazolidines from Substituted Salicylic Nitrones via Visible-Light Photocatalysis
  作者：Graham Haun、Alyson N. Paneque、David W. Almond、Brooke E. Austin、Gustavo Moura-Letts

  DOI：10.1021/acs.orglett.9b00097

  日期：2019.3.1

  reports the first redox-neutral visible-light photocatalytic intramolecular dipolar cycloaddition for the diastereoselective synthesis of chromenoisoxazolidines. The authors have found that alkenylphenyl nitrones with a diverse substitution pattern on the aromatic ring and the alkenyl substituent undergo visible-light-promoted cycloadditions in the presence of catalytic amounts of Ru(bpy)3Cl2 in high

  这项工作报告了首次非氧化还原中性可见光光催化分子内偶极环加成用于非对映选择性合成苯并异恶唑烷。作者已经发现，在催化量的Ru（bpy）3 Cl 2的存在下，在芳环和烯基取代基上具有不同取代模式的烯基苯基硝酮经历了可见光促进的环加成反应，并具有高收率和选择性。有证据表明，拟议的氧化还原中性途径是该转化的主要光氧化还原机理。
• 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVES AND DRUGS CONTAINING SAME
  申请人：Nakashima Hisashi

  公开号：US20100075943A1

  公开（公告）日：2010-03-25

  It is to provide a novel compound useful for preventing and/or treating diseases that involves 11β-hydroxysteroid dehydrogenase 1, particularly diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metabolic syndrome. It is an 1-adamantyl azetidin-2-one derivative represented by the following general formula (1) or salt thereof, or their solvate. [wherein A ring represents C 6-10 aryl group, 5- to 14-membered heteroaryl group, R 1 is a hydrogen atom, halogen atom, C 1-6 alkoxycarbonyl group, hydroxyl group, carboxyl group or carbamoyl group; R 2 and R 3 are the same or different and are a C 1-6 alkyl group; R 4 , R 5 , and R 6 are same or different, and are a hydrogen atom, halogen atom, C 1-6 alkyl group, C 1-6 alkoxy group, C 6-10 aryl group, or R 4 and R 5 , or R 5 and R 6 may together form a C 1-3 alkylenedioxy group, R 7 and R 8 are the same of different and represent a hydrogen atom or C 1-6 alkyl group, or may together form a C 3-6 cyclic hydrocarbon group, n represents an integer of 0 or 1]

  这是提供一种新型化合物，用于预防和/或治疗涉及11β-羟基类固醇脱氢酶1的疾病，特别是糖尿病、胰岛素抵抗、糖尿病并发症、肥胖、血脂异常、高血压、脂肪肝或代谢综合征的化合物。它是由以下通用式（1）代表的1-金刚烷基氮杂环丙酮衍生物，或其盐，或它们的溶剂。【其中，A环代表C6-10芳基，5-至14-成员杂芳基，R1是氢原子，卤原子，C1-6烷氧羰基，羟基，羧基或氨基羰基；R2和R3相同或不同，是C1-6烷基；R4、R5和R6相同或不同，是氢原子，卤原子，C1-6烷基，C1-6烷氧基，C6-10芳基，或R4和R5，或R5和R6可以一起形成C1-3烷二氧基基团，R7和R8相同或不同，代表氢原子或C1-6烷基，或者可以一起形成C3-6环烃基团，n表示0或1的整数】。
• A convenient synthesis of α,α′- homo- and α,α′-hetero-bifunctionalized poly(ε-caprolactone)s by ring opening polymerization: The potentially valuable precursors for miktoarm star copolymers
  作者：Sachin S. Patil、Bhausaheb V. Tawade、Prakash P. Wadgaonkar

  DOI：10.1002/pola.27924

  日期：2016.3.15

  (3‐allyl‐2‐(prop‐2‐yn‐1‐yloxy)phenyl)methanol each containing two reactive functionalities viz. allyl, allyloxy and allyl, propargyloxy, respectively, were synthesized from 3‐allylsalicyaldehyde as a starting material. Well defined α‐allyl, α′‐allyloxy and α‐allyl, α′‐propargyloxy bifunctionalized poly(ε‐caprolactone)s with molecular weights in the range 4200–9500 and 3600–10,900 g/mol and molecular weight distributions

  两种新的开环聚合（ROP）引发剂，分别是（3-烯丙基-2-（烯丙氧基）苯基）甲醇和（3-烯丙基-2-（prop-2-yn-1-基氧基）苯基）甲醇，每个包含两个反应性官能团即。烯丙基，烯丙氧基和烯丙基，炔丙基氧基分别以3-烯丙基水醛为原料合成。定义明确的α-烯丙基，α'-烯丙氧基和α-烯丙基，α'-丙炔氧基双官能化聚（ε-己内酯），分子量在4200-9500和3600-10900 g / mol之间，分子量分布在使用这些引发剂通过ε-己内酯的ROP分别合成了1.16-1.18和1.15-1.16。FT-IR，1 H，证实了聚（ε-己内酯）上存在α-烯丙基，α'-烯丙氧基和α-烯丙基，α'-炔丙氧基官能团。13 C NMR光谱和MALDI-TOF分析。两种引发剂对ε-己内酯的ROP动力学研究揭示了关于ε-己内酯消耗和聚合反应受控行为的假一级动力学。α-烯丙基，α'-烯丙氧基官能团在聚（ε-己内
• DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS
  申请人：Hergenrother Paul J.

  公开号：US20120040995A1

  公开（公告）日：2012-02-16

  Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed that have lower neurotoxicity effects than other compounds.

  本实施例揭示了与诱导细胞死亡有关的组合物和方法，例如在癌细胞中。揭示了合成和使用相关化合物的方法，包括在治疗癌症和选择性诱导细胞凋亡方面使用化合物的方法。揭示了具有比其他化合物更低神经毒性影响的化合物。